 |
SK Bioscience (photo = SK Bioscience homepage) |
[Alpha Biz= Reporter Kim Jisun] On the 4th, SK Bioscience announced that it has signed a '2024-2025 seasonal influenza vaccine supply contract.' The contract amount is 26,698,500,000 won, which accounts for 7.23% of the recent revenue.
The contracting party is the South Korean Public Procurement Service, and the demand agency is the Korea Centers for Disease Control and Prevention. The sales and supply area is South Korea. The contract period is from this day until June 30, 2025.
SK Bioscience stated, "Within a range of 10% of the contract quantity for each contracting party, the contract can be modified according to quantity changes. In unavoidable circumstances, the contract can be modified beyond the 10% range through mutual agreement between the parties."
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
